RESUMO
The primary goal of this study was to establish whether inhibition of GABA synthesis was sufficient to induce network hyperexcitability in a rat hippocampal slice model comparable to that seen with GABA receptor blockade. We used field and intracellular recordings from the CA1 region of rat hippocampal slices to determine the physiological effects of blocking GABA synthesis with the convulsant, 3-mercaptoproprionic acid (MPA). We measured the rate of synthesis of GABA and glutamate in slices using 2-13C-glucose as a label source and liquid chromatography-tandem mass spectrometry. There was little effect of 3.5mM MPA on evoked events under control recording conditions. Tissue excitability was enhanced following a series of stimulus trains; this effect was enhanced when GABA transport was blocked. Evoked inhibitory potentials (IPSPs) failed following repetitive stimulation and MPA. Spontaneous epileptiform activity was seen reliably with elevated extracellular potassium (5mM). GABA synthesis decreased by 49% with MPA alone and 45% with the combination of MPA and excess potassium; GABA content was not substantially altered. Our data indicate: (1) GABAergic inhibition cannot be significantly compromised by MPA without network activation; (2) GABAergic synaptic inhibition is mediated by newly synthesized GABA; (3) there is a depletable pool of GABA that can sustain GABAergic inhibition when synthesis is impaired under basal, but not activated conditions; (4) overt hyperexcitability is only seen when newly synthesized GABA levels are low.
Assuntos
Antagonistas de Aminoácidos Excitatórios/farmacologia , Hipocampo/fisiologia , Neurônios/fisiologia , Ácido gama-Aminobutírico/biossíntese , Ácido 3-Mercaptopropiônico/farmacologia , Animais , Cromatografia Líquida de Alta Pressão , Creatina/metabolismo , Eletrofisiologia , GABAérgicos/farmacologia , Ácido Glutâmico/metabolismo , Glutamina/metabolismo , Hipocampo/citologia , Potenciais da Membrana/efeitos dos fármacos , Rede Nervosa/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Potássio/farmacologia , Ratos , Convulsões/patologia , Convulsões/fisiopatologia , Espectrometria de Massas em TandemRESUMO
High anion gap metabolic acidosis in adults is a severe metabolic disorder for which the primary organic acid usually is apparent by clinical history and standard laboratory testing. We report a case of recurrent high anion gap metabolic acidosis in a 48-year-old man who initially presented with anorexia and malaise. Physical examination was unrevealing. Arterial pH was 6.98, P co 2 was 5 mm Hg, and chemistry tests showed a bicarbonate level of 3 mEq/L (3 mmol/L), anion gap of 32 mEq/L (32 mmol/L), and a negative toxicology screen result, except for an acetaminophen (paracetamol) level of 7.5 mug/mL. Metabolic acidosis resolved with administration of intravenous fluids. Subsequently, he experienced 5 more episodes of high anion gap metabolic acidosis during an 8-month span. Methanol, ethylene glycol, acetone, ethanol, d -lactate, and hippuric acid screens were negative. Lactate levels were modestly elevated, and acetaminophen levels were elevated for 5 of 6 admissions. These episodes defied explanation until 3 urinary organic acid screens, obtained on separate admissions, showed striking elevations of 5-oxoproline levels. Inborn errors of metabolism in the gamma-glutamyl cycle causing recurrent 5-oxoprolinuria and high anion gap metabolic acidosis are rare, but well described in children. Recently, there have been several reports of apparent acquired 5-oxoprolinuria and high anion gap metabolic acidosis in adults in association with acetaminophen use. Acetaminophen may, in susceptible individuals, disrupt regulation of the gamma-glutamyl cycle and result in excessive 5-oxoproline production. Suspicion for 5-oxoproline-associated high anion gap metabolic acidosis should be entertained when the cause of high anion gap metabolic acidosis remains poorly defined, the anion gap cannot be explained reasonably by measured organic acids, and there is concomitant acetaminophen use.
Assuntos
Acetaminofen/efeitos adversos , Equilíbrio Ácido-Base , Acidose/etiologia , Erros Inatos do Metabolismo dos Aminoácidos/metabolismo , Ácido Pirrolidonocarboxílico/urina , Acidose/induzido quimicamente , Acidose/tratamento farmacológico , Erros Inatos do Metabolismo dos Aminoácidos/diagnóstico , Erros Inatos do Metabolismo dos Aminoácidos/genética , Anorexia/etiologia , Bicarbonatos/sangue , Bicarbonatos/uso terapêutico , Dispneia/etiologia , Fadiga/etiologia , Glutationa Sintase/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Urinálise/métodosRESUMO
Inherited metabolic diseases are rare causes of neonatal morbidity, but they are associated with significant recurrence risks for the parents. Prompt identification and treatment of an infant with an inherited metabolic disease can minimize morbidity, mortality, and lifelong developmental problems. Diagnosis often requires specialized laboratory testing, but common laboratory tests can help identify those infants needing further evaluation. This paper reviews the laboratory abnormalities which can be found in various inherited metabolic diseases and can guide selection of specialized metabolic testing. Consultation with a metabolic specialist is essential for timely diagnosis and treatment to ensure the best possible outcome.